{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TAC&page=3", "query": { "intervention": "TAC", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 389, "total_pages": 39, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TAC&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TAC&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T03:40:49.041Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01467505", "title": "An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Telaprevir", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Pegylated Interferon Alfa-2a", "type": "DRUG" }, { "name": "Immunosuppressant Regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 61, "start_date": "2012-02", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2015-06-18", "last_synced_at": "2026-10-21T03:40:49.041Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Bradenton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01467505" }, { "nct_id": "NCT00623766", "title": "Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Corticosteroid: Betamethasone", "type": "DRUG" }, { "name": "Corticosteroid: Dexamethasone", "type": "DRUG" }, { "name": "Corticosteroid: Fludrocortisone", "type": "DRUG" }, { "name": "Corticosteroid: Hydrocortisone", "type": "DRUG" }, { "name": "Corticosteroid: Meprednisone", "type": "DRUG" }, { "name": "Corticosteroid: Methylprednisolone", "type": "DRUG" }, { "name": "Corticosteroid: Prednisolone", "type": "DRUG" }, { "name": "Corticosteroid: Prednisone", "type": "DRUG" }, { "name": "Corticosteroid: Triamcinolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 99, "start_date": "2008-07", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2014-06-09", "last_synced_at": "2026-10-21T03:40:49.041Z", "location_count": 14, "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 11 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Maywood", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00623766" }, { "nct_id": "NCT02242630", "title": "Relationship to Dose of Triamcinolone Acetonide and Methylyprednisolone to Improvement in Subacromial Bursitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Subacromial Bursitis", "Shoulder Pain" ], "interventions": [ { "name": "Methylprednisolone, 20 mg", "type": "DRUG" }, { "name": "Methylprednisolone, 40 mg", "type": "DRUG" }, { "name": "Triamcinolone, 20 mg", "type": "DRUG" }, { "name": "Triamcinolone, 40 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Keesler Air Force Base Medical Center", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2014-09", "completion_date": "2016-03", "has_results": true, "last_update_posted_date": "2016-12-14", "last_synced_at": "2026-10-21T03:40:49.041Z", "location_count": 1, "location_summary": "Keesler Air Force Base, Mississippi", "locations": [ { "city": "Keesler Air Force Base", "state": "Mississippi" } ], "official_url": "https://clinicaltrials.gov/study/NCT02242630" }, { "nct_id": "NCT02592629", "title": "The Efficacy of Local Anesthetics to Reduce Shoulder Pain Post-Steroid Injections", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Shoulder Pain" ], "interventions": [ { "name": "lidocaine", "type": "DRUG" }, { "name": "ethyl chloride", "type": "DRUG" }, { "name": "Kenalog", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Milton S. Hershey Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 19, "start_date": "2016-02-01", "completion_date": "2017-06-20", "has_results": true, "last_update_posted_date": "2018-10-16", "last_synced_at": "2026-10-21T03:40:49.041Z", "location_count": 1, "location_summary": "Hershey, Pennsylvania", "locations": [ { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02592629" }, { "nct_id": "NCT01356602", "title": "Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Gouty Arthritis" ], "interventions": [ { "name": "Canakinumab pre-filled syringe", "type": "DRUG" }, { "name": "Canakinumab lyophilized powder", "type": "DRUG" }, { "name": "Triamcinolone Acetonide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 397, "start_date": "2011-05", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2014-01-29", "last_synced_at": "2026-10-21T03:40:49.041Z", "location_count": 69, "location_summary": "Anniston, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 62 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Gulf Shores", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01356602" }, { "nct_id": "NCT02420457", "title": "Tracking Outcomes in Pain Patients Using Fitness Devices", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Pain", "Back Pain" ], "interventions": [ { "name": "Epidural injection", "type": "PROCEDURE" }, { "name": "Epidural steroid injection as determined by routine care provider", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2015-03", "completion_date": "2018-05", "has_results": false, "last_update_posted_date": "2019-04-25", "last_synced_at": "2026-10-21T03:40:49.041Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02420457" }, { "nct_id": "NCT03841097", "title": "Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Kidney Transplant; Complications" ], "interventions": [ { "name": "Extended Release Tacrolimus Tablets", "type": "DRUG" }, { "name": "Immediate Release Tacrolimus Capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Roy D. Bloom, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 60, "start_date": "2019-11-11", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-10-21T03:40:49.041Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03841097" }, { "nct_id": "NCT00001249", "title": "Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, T-Cell", "Lymphoma, T-Cell, Cutaneous" ], "interventions": [ { "name": "Yttrium-90 radiolabeled anti-Tac antibody", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 30, "start_date": "1989-12", "completion_date": "2000-10", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-10-21T03:40:49.041Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001249" }, { "nct_id": "NCT00043667", "title": "Daclizumab Injections to Treat Non-Infectious Sight-Threatening Uveitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Uveitis" ], "interventions": [ { "name": "Daclizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Eye Institute (NEI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 15, "start_date": "2002-08", "completion_date": "2004-10", "has_results": false, "last_update_posted_date": "2008-03-04", "last_synced_at": "2026-10-21T03:40:49.041Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00043667" }, { "nct_id": "NCT03781414", "title": "Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Transplant Rejection" ], "interventions": [ { "name": "CFZ533", "type": "BIOLOGICAL" }, { "name": "Tacrolimus - MMF - corticosteroids", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 129, "start_date": "2019-10-07", "completion_date": "2023-04-20", "has_results": true, "last_update_posted_date": "2025-05-16", "last_synced_at": "2026-10-21T03:40:49.041Z", "location_count": 9, "location_summary": "Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03781414" } ] }